BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sax DS, Kornetsky C, Kim A. Lack of hepatotoxicity with naltrexone treatment. J Clin Pharmacol 1994;34:898-901. [PMID: 7983232 DOI: 10.1002/j.1552-4604.1994.tb04002.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Yen M, Ko H, Tang F, Lu R, Hong J. Study of hepatotoxicity of naltrexone in the treatment of alcoholism. Alcohol 2006;38:117-20. [DOI: 10.1016/j.alcohol.2006.05.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
2 Comer SD, Sullivan MA, Hulse GK. Sustained-release naltrexone: novel treatment for opioid dependence. Expert Opinion on Investigational Drugs 2007;16:1285-94. [DOI: 10.1517/13543784.16.8.1285] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 3.1] [Reference Citation Analysis]
3 Marrazzi MA, Wroblewski JM, Kinzie J, Luby ED. High-Dose Naltrexone and Liver Function Safety. The American Journal on Addictions 1997;6:21-9. [DOI: 10.1111/j.1521-0391.1997.tb00388.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
4 Yoon G, Kim SW, Thuras P, Westermeyer J. Safety, tolerability, and feasibility of high-dose naltrexone in alcohol dependence: an open-label study. Hum Psychopharmacol 2011;26:125-32. [PMID: 21437991 DOI: 10.1002/hup.1183] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
5 Kim SW, Grant JE, Yoon G, Williams KA, Remmel RP. Safety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatients. Clin Neuropharmacol 2006;29:77-9. [PMID: 16614539 DOI: 10.1097/00002826-200603000-00004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
6 Olson GA, Olson RD, Kastin AJ. Endogenous opiates: 1994. Peptides 1995;16:1517-55. [DOI: 10.1016/0196-9781(95)02063-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sedky K, Nazir R, Joshi A, Kaur G, Lippmann S. Which psychotropic medications induce hepatotoxicity? General Hospital Psychiatry 2012;34:53-61. [DOI: 10.1016/j.genhosppsych.2011.10.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
8 Sinclair JMA, Chambers SE, Shiles CJ, Baldwin DS. Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence. Drug Saf 2016;39:627-45. [DOI: 10.1007/s40264-016-0416-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 5.7] [Reference Citation Analysis]
9 Cropsey KL, Villalobos GC, St Clair CL. Pharmacotherapy treatment in substance-dependent correctional populations: a review. Subst Use Misuse 2005;40:1983-99, 2043-8. [PMID: 16282089 DOI: 10.1080/10826080500294866] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
10 Terg R, Coronel E, Sordá J, Muñoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002;37:717-22. [PMID: 12445410 DOI: 10.1016/s0168-8278(02)00318-5] [Cited by in Crossref: 113] [Cited by in F6Publishing: 22] [Article Influence: 5.9] [Reference Citation Analysis]
11 Haber PS, Warner R, Seth D, Gorrell MD, McCaughan GW. Pathogenesis and management of alcoholic hepatitis. J Gastroenterol Hepatol. 2003;18:1332-1344. [PMID: 14675260 DOI: 10.1046/j.1440-1746.2003.03217.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 2.9] [Reference Citation Analysis]
12 Davis M. Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics. Clin Pharmacokinet 2007;46:825-50. [PMID: 17854233 DOI: 10.2165/00003088-200746100-00002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
13 Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O'Brien CP. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006;63:210-8. [PMID: 16461865 DOI: 10.1001/archpsyc.63.2.210] [Cited by in Crossref: 221] [Cited by in F6Publishing: 205] [Article Influence: 13.8] [Reference Citation Analysis]
14 Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, Springer SA. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone. J Subst Abuse Treat 2014;47:35-40. [PMID: 24674234 DOI: 10.1016/j.jsat.2014.02.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
15 Younger JW, Zautra AJ, Cummins ET. Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology. PLoS One 2009;4:e5180. [PMID: 19365548 DOI: 10.1371/journal.pone.0005180] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
16 Yoon G, Kim SW, Petrakis IL, Westermeyer J. High-Dose Naltrexone Treatment and Gender in Alcohol Dependence. Clin Neuropharmacol 2016;39:165-8. [PMID: 27046656 DOI: 10.1097/WNF.0000000000000152] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Roy DN, Goswami R. Drugs of abuse and addiction: A slippery slope toward liver injury. Chem Biol Interact. 2016;255:92-105. [PMID: 26409324 DOI: 10.1016/j.cbi.2015.09.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
18 Brewer C, Wong VS. Naltrexone: report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature. Addiction Biology 2004;9:81-7. [DOI: 10.1080/13556210410001674130] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
19 Choi YS, Billings J. Opioid Antagonists. Journal of Pain and Symptom Management 2002;24:71-90. [DOI: 10.1016/s0885-3924(02)00424-4] [Cited by in Crossref: 105] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
20 Nielsen SMB, Vinther-jensen T, Nielsen JE, Nørremølle A, Hasholt L, Hjermind LE, Josefsen K. Liver function in Huntington's disease assessed by blood biochemical analyses in a clinical setting. Journal of the Neurological Sciences 2016;362:326-32. [DOI: 10.1016/j.jns.2016.02.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
21 Mani AR, Rasool R, Montagnese S, Dehpour AR. Endogenous opioids and liver disease. Scandinavian Journal of Gastroenterology 2009;41:1-11. [DOI: 10.1080/00365520500287533] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
22 Cashman JR, Azar MR. Potent inhibition of alcohol self-administration in alcohol-preferring rats by a κ-opioid receptor antagonist. J Pharmacol Exp Ther 2014;350:171-80. [PMID: 24817033 DOI: 10.1124/jpet.114.214262] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
23 Mansour-Ghanaei F, Taheri A, Froutan H, Ghofrani H, Nasiri-Toosi M, Bagherzadeh AH, Farahvash MJ, Mirmomen S, Ebrahimi-Dariani N, Farhangi E, Pourrasouli Z. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 2006; 12(7): 1125-1128 [PMID: 16534857 DOI: 10.3748/wjg.v12.i7.1125] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
24 Comer SD, Collins ED, Kleber HD, Nuwayser ES, Kerrigan JH, Fischman MW. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl) 2002;159:351-60. [PMID: 11823887 DOI: 10.1007/s002130100909] [Cited by in Crossref: 123] [Cited by in F6Publishing: 108] [Article Influence: 5.9] [Reference Citation Analysis]